P2RX7 Purinoceptor: A Therapeutic Target for Ameliorating the Symptoms of Duchenne Muscular Dystrophy

PLoS Medicine

Volumn 12, Issue 10, 2015, Pages

  Sinadinos, Anthony ^a   Young, Christopher N J ^a   Al Khalidi, Rasha ^a   Teti, Anna ^b   Kalinski, Paweł ^c   Mohamad, Shafini ^a   Floriot, Léonore ^d   Henry, Tiphaine ^d   Tozzi, Gianluca ^a   Jiang, Taiwen ^a   Wurtz, Olivier ^e   Lefebvre, Alexis ^d   Shugay, Mikhail ^f   Tong, Jie ^a   Vaudry, David ^e   Arkle, Stephen ^a   doRego, Jean Claude ^d,g   Górecki, Dariusz C ^a  

^a UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITÉ DE ROUEN   (France)

^e Université de Rouen   (France)

^f SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

^g CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CREATINE KINASE; DYSTROPHIN; PURINERGIC P2X7 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; P2RX7 PROTEIN, MOUSE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG TARGETING; DUCHENNE MUSCULAR DYSTROPHY; FEMALE; GENE MUTATION; GRIP STRENGTH; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOLOCALIZATION; INFLAMMATION; LOCOMOTION; LYMPHOBLAST; MALE; MORPHOMETRICS; MOUSE; MUSCLE STRENGTH; MYOFIBROSIS; NONHUMAN; POLYMERASE CHAIN REACTION; RNA SEQUENCE; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; DISEASE MODEL; GENE THERAPY; GENETICS; MUSCULAR DYSTROPHY, DUCHENNE; PHENOTYPE; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; GENETIC THERAPY; MICE; MICE, INBRED MDX; MUSCULAR DYSTROPHY, DUCHENNE; PHENOTYPE; RECEPTORS, PURINERGIC P2X7; SIGNAL TRANSDUCTION;

EID: 84946022511     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001888     Document Type: Article

References (76)

1. Davies KE, Nowak KJ, Molecular mechanisms of muscular dystrophies: old and new players. Nat Rev Mol Cell Biol. 2006;7:762–773. 16971897
2. Snow WM, Anderson JE, Jakobson LS, Neuropsychological and neurobehavioral functioning in Duchenne muscular dystrophy: a review. Neurosci Biobehav Rev. 2013;37:743–752. doi: 10.1016/j.neubiorev.2013.03.016 23545331
3. Rufo A, Del Fattore A, Capulli M, Carvello F, De Pasquale L, Ferrari S, et al. Mechanisms inducing low bone density in Duchenne muscular dystrophy in mice and humans. J Bone Miner Res. 2011;26:1891–1903. doi: 10.1002/jbmr.410 21509823
4. van Putten M, Hulsker M, Nadarajah VD, van Heiningen SH, van Huizen E, van Iterson M, et al. The effects of low levels of dystrophin on mouse muscle function and pathology. PLoS ONE. 2012;7:e31937. doi: 10.1371/journal.pone.0031937 22359642
5. Percival JM, Whitehead NP, Adams ME, Adamo CM, Beavo JA, Froehner SC, Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy. J Pathol. 2012;228:77–87. doi: 10.1002/path.4054 22653783
6. Ferrari D, Munerati M, Melchiorri L, Hanau S, di Virgilio F, Baricordi OR, Responses to extracellular ATP of lymphoblastoid cell lines from Duchenne muscular dystrophy patients. Am J Physiol. 1994;267:C886–C892. 7524344
7. Yeung D, Zablocki K, Lien CF, Jiang T, Arkle S, Brutkowski W, et al. Increased susceptibility to ATP via alteration of P2X receptor function in dystrophic mdx mouse muscle cells. FASEB J. 2006;20:610–620. 16581969
8. Rawat R, Cohen TV, Ampong B, Francia D, Henriques-Pons A, Hoffman EP, et al. Inflammasome up-regulation and activation in dysferlin-deficient skeletal muscle. Am J Pathol. 2010;176:2891–2900. doi: 10.2353/ajpath.2010.090058 20413686
9. Young CN, Brutkowski W, Lien CF, Arkle S, Lochmuller H, Zablocki K, et al. P2X7 purinoceptor alterations in dystrophic mdx mouse muscles: relationship to pathology and potential target for treatment. J Cell Mol Med. 2012;16:1026–1037. doi: 10.1111/j.1582-4934.2011.01397.x 21794079
10. Valladares D, Almarza G, Contreras A, Pavez M, Buvinic S, Jaimovich E, et al. Electrical stimuli are anti-apoptotic in skeletal muscle via extracellular ATP. Alteration of this signal in Mdx mice is a likely cause of dystrophy. PLoS ONE. 2013;8:e75340. doi: 10.1371/journal.pone.0075340 24282497
11. Young CNJ, Sinadinos A, Gorecki DC, P2X receptor signaling in skeletal muscle health and disease. Wiley Interdiscip Rev Membr Transp Signal. 2013;2:265–274.
12. Young C, Sinadinos A, Lefebvre A, Chan P, Arkle S, Vaudry D, et al. A novel mechanism of autophagic cell death in dystrophic muscle regulated by P2RX7 receptor large-pore formation and HSP90. Autophagy. 2015;11:113–130. doi: 10.4161/15548627.2014.994402 25700737
13. Idzko M, Ferrari D, Eltzschig HK, Nucleotide signalling during inflammation. Nature. 2014;509:310–317. doi: 10.1038/nature13085 24828189
14. Di Virgilio F, Liaisons dangereuses: P2X(7) and the inflammasome. Trends Pharmacol Sci. 2007;28:465–472. 17692395
15. Sandona D, Gastaldello S, Martinello T, Betto R, Characterization of the ATP-hydrolysing activity of alpha-sarcoglycan. Biochem J. 2004;381:105–112. 15032752
16. North RA, Jarvis MF, P2X receptors as drug targets. Mol Pharmacol. 2013;83:759–769. doi: 10.1124/mol.112.083758 23253448
17. Masin M, Young C, Lim K, Barnes SJ, Xu XJ, Marschall V, et al. Expression, assembly and function of novel C-terminal truncated variants of the mouse P2X7 receptor: re-evaluation of P2X7 knockouts. Br J Pharmacol. 2012;165:978–993. doi: 10.1111/j.1476-5381.2011.01624.x 21838754
18. Nicke A, Kuan YH, Masin M, Rettinger J, Marquez-Klaka B, Bender O, et al. A functional P2X7 splice variant with an alternative transmembrane domain 1 escapes gene inactivation in P2X7 knock-out mice. J Biol Chem. 2009;284:25813–25822. doi: 10.1074/jbc.M109.033134 19546214
19. Chessell IP, Hatcher JP, Bountra C, Michel AD, Hughes JP, Green P, et al. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain. 2005;114:386–396. 15777864
20. Solle M, Labasi J, Perregaux DG, Stam E, Petrushova N, Koller BH, et al. Altered cytokine production in mice lacking P2X(7) receptors. J Biol Chem. 2001;276:125–132. 11016935
21. Grounds MD, Radley HG, Lynch GS, Nagaraju K, De Luca A, Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. Neurobiol Dis. 2008;31:1–19. doi: 10.1016/j.nbd.2008.03.008 18499465
22. McNally EM, New approaches in the therapy of cardiomyopathy in muscular dystrophy. Annu Rev Med. 2007;58:75–88. 17217326
23. Gourine AV, Poputnikov DM, Zhernosek N, Melenchuk EV, Gerstberger R, Spyer KM, et al. P2 receptor blockade attenuates fever and cytokine responses induced by lipopolysaccharide in rats. Br J Pharmacol. 2005;146:139–145. 15965498
24. Ardissone V, Radaelli E, Zaratin P, Ardizzone M, Ladel C, Gattorno M, et al. Pharmacologic P2X purinergic receptor antagonism in the treatment of collagen-induced arthritis. Arthritis Rheum. 2011;63:3323–3332. doi: 10.1002/art.30556 21792831
25. Amalfitano A, Chamberlain JS, The mdx-amplification-resistant mutation system assay, a simple and rapid polymerase chain reaction-based detection of the mdx allele. Muscle Nerve. 1996;19:1549–1553. 8941268
26. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676–682. doi: 10.1038/nmeth.2019 22743772
27. Schneider CA, Rasband WS, Eliceiri KW, NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671–675. 22930834
28. Briguet A, Courdier-Fruh I, Foster M, Meier T, Magyar JP, Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse. Neuromuscul Disord. 2004;14:675–682. 15351425
29. Gosselin LE, Barkley JE, Spencer MJ, McCormick KM, Farkas GA, Ventilatory dysfunction in mdx mice: impact of tumor necrosis factor-alpha deletion. Muscle Nerve. 2003;28:336–343. 12929194
30. Kamens HM, Crabbe JC, The parallel rod floor test: a measure of ataxia in mice. Nat Protoc. 2007;2:277–281. 17406586
31. Leger M, Quiedeville A, Bouet V, Haelewyn B, Boulouard M, Schumann-Bard P, et al. Object recognition test in mice. Nat Protoc. 2013;8:2531–2537. doi: 10.1038/nprot.2013.155 24263092
32. Straub V, Rafael JA, Chamberlain JS, Campbell KP, Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. J Cell Biol. 1997;139:375–385. 9334342
33. Chen YG, Scheuplein F, Driver JP, Hewes AA, Reifsnyder PC, Leiter EH, et al. Testing the role of P2X7 receptors in the development of type 1 diabetes in nonobese diabetic mice. J Immunol. 2011;186:4278–4284. doi: 10.4049/jimmunol.1003733 21357538
34. Porter JD, Khanna S, Kaminski HJ, Rao JS, Merriam AP, Richmonds CR, et al. A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum Mol Genet. 2002;11:263–272. 11823445
35. Huynh T, Uaesoontrachoon K, Quinn JL, Tatem KS, Heier CR, Van Der Meulen JH, et al. Selective modulation through the glucocorticoid receptor ameliorates muscle pathology in mdx mice. J Pathol. 2013;231:223–235. doi: 10.1002/path.4231 23794417
36. Villalta SA, Nguyen HX, Deng B, Gotoh T, Tidball JG, Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. Hum Mol Genet. 2009;18:482–496. doi: 10.1093/hmg/ddn376 18996917
37. Yeung D, Kharidia R, Brown SC, Gorecki DC, Enhanced expression of the P2X4 receptor in Duchenne muscular dystrophy correlates with macrophage invasion. Neurobiol Dis. 2004;15:212–220. 15006691
38. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007;450:566–569. 18033300
39. Schenk U, Frascoli M, Proietti M, Geffers R, Traggiai E, Buer J, et al. ATP inhibits the generation and function of regulatory T cells through the activation of purinergic P2X receptors. Sci Signal. 2011;4:ra12. doi: 10.1126/scisignal.2001270 21364186
40. Grounds MD, Torrisi J, Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis. FASEB J. 2004;18:676–682. 15054089
41. Kawamura H, Kawamura T, Kanda Y, Kobayashi T, Abo T, Extracellular ATP-stimulated macrophages produce macrophage inflammatory protein-2 which is important for neutrophil migration. Immunology. 2012;136:448–458. doi: 10.1111/j.1365-2567.2012.03601.x 22564028
42. Ward JH, Hierarchical grouping to optimize an objective function. J Am Stat Assoc. 1963;58:236–244.
43. Sacco A, Mourkioti F, Tran R, Choi J, Llewellyn M, Kraft P, et al. Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx/mTR mice. Cell. 2010;143:1059–1071. doi: 10.1016/j.cell.2010.11.039 21145579
44. Pigozzo SR, Da Re L, Romualdi C, Mazzara PG, Galletta E, Fletcher S, et al. Revertant fibers in the mdx murine model of Duchenne muscular dystrophy: an age- and muscle-related reappraisal. PLoS ONE. 2013;8:e72147. doi: 10.1371/journal.pone.0072147 24015212
45. Gorecki DC, Monaco AP, Derry JM, Walker AP, Barnard EA, Barnard PJ, Expression of four alternative dystrophin transcripts in brain regions regulated by different promoters. Hum Mol Genet. 1992;1:505–510. 1307251
46. Browne SE, When too much ATP is a bad thing: a pivotal role for P2X7 receptors in motor neuron degeneration. J Neurochem. 2013;126:301–304. doi: 10.1111/jnc.12321 23773137
47. Vaillend C, Perronnet C, Ros C, Gruszczynski C, Goyenvalle A, Laroche S, et al. Rescue of a dystrophin-like protein by exon skipping in vivo restores GABAA-receptor clustering in the hippocampus of the mdx mouse. Mol Ther. 2010;18:1683–1688. doi: 10.1038/mt.2010.134 20588257
48. Vaillend C, Billard JM, Laroche S, Impaired long-term spatial and recognition memory and enhanced CA1 hippocampal LTP in the dystrophin-deficient Dmd(mdx) mouse. Neurobiol Dis. 2004;17:10–20. 15350961
49. McGaraughty S, Chu KL, Namovic MT, Donnelly-Roberts DL, Harris RR, Zhang XF, et al. P2X7-related modulation of pathological nociception in rats. J Neurosci. 2007;146:1817–1828.
50. Michel AD, Chambers LJ, Walter DS, Negative and positive allosteric modulators of the P2X(7) receptor. Br J Pharmacol. 2008;153:737–750. 18071294
51. Donnelly-Roberts DL, Jarvis MF, Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states. Br J Pharmacol. 2007;151:571–579. 17471177
52. Vidal B, Ardite E, Suelves M, Ruiz-Bonilla V, Janue A, Flick MJ, et al. Amelioration of Duchenne muscular dystrophy in mdx mice by elimination of matrix-associated fibrin-driven inflammation coupled to the alphaMbeta2 leukocyte integrin receptor. Hum Mol Genet. 2012;21:1989–2004. doi: 10.1093/hmg/dds012 22381526
53. Giordano C, Mojumdar K, Liang F, Lemaire C, Li T, Richardson J, et al. Toll-like receptor 4 ablation in mdx mice reveals innate immunity as a therapeutic target in Duchenne muscular dystrophy. Hum Mol Genet. 2014;24:2147–2162. doi: 10.1093/hmg/ddu735 25552658
54. Gussoni E, Pavlath GK, Miller RG, Panzara MA, Powell M, Blau HM, et al. Specific T cell receptor gene rearrangements at the site of muscle degeneration in Duchenne muscular dystrophy. J Immunol. 1994;153:4798–4805. 7963545
55. Spencer MJ, Montecino-Rodriguez E, Dorshkind K, Tidball JG, Helper (CD4(+)) and cytotoxic (CD8(+)) T cells promote the pathology of dystrophin-deficient muscle. Clin Immunol. 2001;98:235–243. 11161980
56. Camirand G, Stephan L, Rousseau J, Sackett MK, Caron NJ, Mills P, et al. Central tolerance to myogenic cell transplants does not include muscle neoantigens. Transplantation. 2008;85:1791–1801. doi: 10.1097/TP.0b013e31817726bc 18580473
57. Altamirano F, Valladares D, Henriquez-Olguin C, Casas M, Lopez JR, Allen PD, et al. Nifedipine treatment reduces resting calcium concentration, oxidative and apoptotic gene expression, and improves muscle function in dystrophic mdx mice. PLoS ONE. 2013;8:e81222. doi: 10.1371/journal.pone.0081222 24349043
58. Friedrich O, Both M, Gillis JM, Chamberlain JS, Fink RH, Mini-dystrophin restores L-type calcium currents in skeletal muscle of transgenic mdx mice. J Physiol. 2004;555:251–265. 14594987
59. Vandebrouck A, Ducret T, Basset O, Sebille S, Raymond G, Ruegg U, et al. Regulation of store-operated calcium entries and mitochondrial uptake by minidystrophin expression in cultured myotubes. FASEB J. 2006;20:136–138. 16254044
60. Martinello T, Baldoin MC, Morbiato L, Paganin M, Tarricone E, Schiavo G, et al. Extracellular ATP signaling during differentiation of C2C12 skeletal muscle cells: role in proliferation. Mol Cell Biochem. 2011;351:183–196. doi: 10.1007/s11010-011-0726-4 21308481
61. Hindi SM, Sato S, Choi Y, Kumar A, Distinct roles of TRAF6 at early and late stages of muscle pathology in the mdx model of Duchenne muscular dystrophy. Hum Mol Genet. 2014;23:1492–1505. doi: 10.1093/hmg/ddt536 24163132
62. Gutpell KM, Hrinivich WT, Hoffman LM, Skeletal muscle fibrosis in the mdx/utrn+/- mouse validates its suitability as a murine model of Duchenne muscular dystrophy. PLoS ONE. 2015;10:e0117306. doi: 10.1371/journal.pone.0117306 25607927
63. Narita S, Yorifuji H, Centrally nucleated fibers (CNFs) compensate the fragility of myofibers in mdx mouse. Neuroreport. 1999;10:3233–3235. 10574566
64. Knuesel I, Mastrocola M, Zuellig RA, Bornhauser B, Schaub MC, Fritschy JM, Short communication: altered synaptic clustering of GABAA receptors in mice lacking dystrophin (mdx mice). Eur J Neurosci. 1999;11:4457–4462. 10594673
65. Krasowska E, Zablocki K, Gorecki DC, Swinny JD, Aberrant location of inhibitory synaptic marker proteins in the hippocampus of dystrophin-deficient mice: implications for cognitive impairment in duchenne muscular dystrophy. PLoS ONE. 2014;9:e108364. doi: 10.1371/journal.pone.0108364 25260053
66. Sim JA, Young MT, Sung HY, North RA, Surprenant A, Reanalysis of P2X7 receptor expression in rodent brain. J Neurosci. 2004;24:6307–6314. 15254086
67. Nico B, Paola Nicchia G, Frigeri A, Corsi P, Mangieri D, Ribatti D, et al. Altered blood-brain barrier development in dystrophic MDX mice. Neuroscience. 2004;125:921–935. 15120852
68. Perry VH, Contribution of systemic inflammation to chronic neurodegeneration. Acta Neuropathol. 2010;120:277–286. doi: 10.1007/s00401-010-0722-x 20644946
69. Bhattacharya A, Wang Q, Ao H, Shoblock JR, Lord B, Aluisio L, et al. Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567. Br J Pharmacol. 2013;170:624–640. doi: 10.1111/bph.12314 23889535
70. Kvist TM, Schwarz P, Jorgensen NR, The P2X7 receptor: a key player in immune-mediated bone loss? ScientificWorldJournal. 2014;2014:954530. doi: 10.1155/2014/954530 24574936
71. Abou-Khalil R, Yang F, Mortreux M, Lieu S, Yu YY, Wurmser M, et al. Delayed bone regeneration is linked to chronic inflammation in murine muscular dystrophy. J Bone Miner Res. 2014;29:304–315. doi: 10.1002/jbmr.2038 23857747
72. Yablonka-Reuveni Z, Anderson JE, Satellite cells from dystrophic (mdx) mice display accelerated differentiation in primary cultures and in isolated myofibers. Dev Dyn. 2006;235:203–212. 16258933
73. Ghahramani Seno MM, Graham IR, Athanasopoulos T, Trollet C, Pohlschmidt M, Crompton MR, et al. RNAi-mediated knockdown of dystrophin expression in adult mice does not lead to overt muscular dystrophy pathology. Hum Mol Genet. 2008;17:2622–2632. doi: 10.1093/hmg/ddn162 18511456
74. Merrick D, Stadler LK, Larner D, Smith J, Muscular dystrophy begins early in embryonic development deriving from stem cell loss and disrupted skeletal muscle formation. Dis Model Mech. 2009;2:374–388. doi: 10.1242/dmm.001008 19535499
75. Arulkumaran N, Unwin RJ, Tam FWK, A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases. Expert Opin Inv Drug. 2011;20:897–915.
76. Fowler BJ, Gelfand BD, Kim Y, Kerur N, Tarallo V, Hirano Y, et al. Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity. Science. 2014;346:1000–1003. doi: 10.1126/science.1261754 25414314